CytoMed Therapeutics
GDTC
1 hedge funds and large institutions have $28 invested in CytoMed Therapeutics in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0.04% less ownership
Funds ownership: 0.04% → 0% (-0.04%)
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less capital invested
Capital invested by funds: $21.5K → $28 (-$21.4K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$17.1K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.55K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
1
Tower Research Capital (TRC)
New York
| $28 | -$2.55K | -869 | -99% |
|
|
2
UBS Group
Zurich,
Switzerland
| – | -$17.1K | -3,500 | Closed |
|
GDTC Hedge Fund Activity: Q1 2024 in Review
1 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in CytoMed Therapeutics (GDTC) for Q1 2024, worth a combined $28 — down 100% from $21.5K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of GDTC and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was UBS Group, exiting entirely with an estimated $17.1K sold.
- 1 institutional investor held CytoMed Therapeutics (GDTC) as of Q1 2024, down from 2 in Q4 2023.
- Funds reported $28 of CytoMed Therapeutics stock for Q1 2024, down 100% quarter-over-quarter.
- 0 funds opened new CytoMed Therapeutics positions in Q1 2024 and 1 closed out, a net change of -1 holder.
- The largest CytoMed Therapeutics seller in Q1 2024 was UBS Group, an estimated $17.1K sold.
Based on aggregated 13F filings for Q1 2024.